Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
10:20am, Tuesday, 06'th May 2025
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Recursion to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 06'th May 2025
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in th
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
03:02pm, Monday, 05'th May 2025
Recursion Pharmaceuticals (RXRX -15.53%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage bio
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
01:37pm, Monday, 05'th May 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Najat Khan - Chief R&D Of
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
08:15am, Monday, 05'th May 2025
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
06:00am, Monday, 05'th May 2025
SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and fina
Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings
04:02am, Monday, 05'th May 2025
AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug discover
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
12:45pm, Sunday, 04'th May 2025
SALT LAKE CITY, May 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced preliminary safety and efficacy
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
06:55pm, Monday, 28'th Apr 2025
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day.
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
08:27am, Monday, 28'th Apr 2025
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
3 Monster Stocks to Hold for the Next 10 Years
09:45am, Wednesday, 23'rd Apr 2025
Got a little money and a lot of time? Say, 10 years or more?
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
08:34pm, Tuesday, 22'nd Apr 2025
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data dur
Investment strategist picks 3 ‘new age' healthcare stocks to buy
06:42am, Sunday, 20'th Apr 2025
Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors.
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
09:00am, Friday, 18'th Apr 2025
Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the sa
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
08:30am, Wednesday, 16'th Apr 2025
PHILADELPHIA , April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading
